News
Schedule for TBIG Fall 2025
TBIG Schedule for Fall 2025:
-
-
- September 4, 2025: Intro Session (goals for upcoming year) - Internal
- September 18, 2025: Dr. Cynthia Tschampl, Brandeis University - External
- October 16, 2025: Lauren Linde and Rachel Yorlets - Internal
- October 23, 2025: David Gillerman and Sophie Reilly - Internal
- November 6, 2025: Dr. Allison Portnoy and Amy Zheng- Internal
- November 13, 2025: Dr. Igor Kramnik - Internal
- December 4, 2025: TBD - External
- December 18, 2025: Genevieve Dupuis & Dr. Jackie Dinh - Internal
-
PUBLICATION ALERT: Impact of pharmacogenetics on pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trial
Congrats Dr. Brooks and others!
Dr. Brooke Nichols featured in Salon: From dread to action: Tracking the Trump-Musk death toll from cuts to USAID
From dread to action: Tracking the Trump-Musk death toll from cuts to USAID | Salon.com
PUBLICATION ALERT: Impact of US Government funding cessation on TB care and prevention: a multicountry survey in Africa
Koura KG, Soe AN, Dlodlo RA, Lin Y, Sinha P, Badoum G, Dogo MF, Horsburgh CR, Harries AD. Impact of US Government funding cessation on TB care and prevention: a multicountry survey in Africa. Int J Tuberc Lung Dis. 2025 May 25;29(5):239-241. doi: 10.5588/ijtld.24.0215. PMID: 40281676.
PUBLICATION ALERT: Barriers to recruitment of an observational SARS-CoV-2 emergency department cohort at Boston Medical Center.
Thomson SJ, Mistry R, Bayly H, Overbeck V, Sagar M, Schechter-Perkins EM, White LF, Jacobson KR, Bouton TC.
BMC Emerg Med. 2025 Apr 20;25(1):68. doi: 10.1186/s12873-025-01224-w.
PMID: 40254607
PUBLICATION ALERT: Health impact and cost-effectiveness of testing and treatment of Mycobacterium tuberculosis infection among Asian and Hispanic persons with diagnosed diabetes in the United States – PubMed
PUBLICATIONS ALERT: Three articles focused on optimizing treatment strategies for multidrug-resistant tuberculosis (MDR-TB)
- Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy
- Efficacy and Safety of Higher Doses of Levofloxacin for MDR-TB: A Randomized Placebo-controlled Phase 2 Trial
- Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial
Submissions to scientific sessions for The Union due April 9
Scientific submissions due April 9, 2025
PUBLICATION ALERT: Inferring bivariate associations with continuous data from studies using respondent-driven sampling
Dr. Malatesta and others publish "Inferring bivariate associations with continuous data from studies using respondent-driven sampling" in the Journal of the Royal Statistical Society.
PUBLICATION ALERT: The risk of rifampicin-resistant TB after drug-susceptible TB treatment
Annie Shapiro and others publish "The risk of rifampicin-resistant TB after drug-susceptible TB treatment" in IJTLD!
The risk of rifampicin-resistant TB after drug-susceptible TB treatment - PubMed